Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis
Study of 12 Cases of Autoimmune Encephalitis With Anti-NMDA Receptor Antibodies Following Herpetic Encephalitis and Review of the Literature
| Sponsors |
Lead Sponsor: Hospices Civils de Lyon |
||||||
|---|---|---|---|---|---|---|---|
| Source | Hospices Civils de Lyon | ||||||
| Brief Summary | Herpes Simplex Virus encephalitis is the most common infectious encephalitis, with an estimated annual incidence of 1 / 250,000 to 1 / 500,000 in industrialized countries. Despite a widely used antiviral treatment, the prognosis remains poor with a mortality of 5 to 20% and a considerable morbidity rate. One of the contributing factors of bad prognosis is the development of encephalitis mediated by autoantibodies, most often directed against NMDA receptors, in the weeks following viral encephalitis. The description of this pathology is recent, the pathophysiology of this process remains poorly understood, and the management of these patients is not yet codified. |
||||||
| Overall Status | Recruiting | ||||||
| Start Date | April 1, 2020 | ||||||
| Completion Date | October 1, 2020 | ||||||
| Primary Completion Date | June 1, 2020 | ||||||
| Study Type | Observational | ||||||
| Primary Outcome |
|
||||||
| Enrollment | 12 | ||||||
| Condition | |||||||
| Intervention |
Intervention Type: Other Intervention Name: Description and analysis Description: Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up. Arm Group Label: Cohort NMDARE-HSE |
||||||
| Eligibility |
Sampling Method: Non-Probability Sample
Criteria:
Inclusion Criteria: - Clinical autoimmune encephalitis with anti-NMDA antibodies and documented by CBA in the CSF - After a herpetic encephalitis documented by a positive viral PCR for HSV in the CSF - Without age limit Exclusion Criteria- No respect of inclusion criteria Gender: All Minimum Age: N/A Maximum Age: N/A Healthy Volunteers: No |
||||||
| Overall Official |
|
||||||
| Overall Contact |
Last Name: Jérôme Honnorat, PhD Phone: 04 72 35 78 06 Email: [email protected] |
||||||
| Location |
|
||||||
| Location Countries |
France |
||||||
| Verification Date |
April 2020 |
||||||
| Responsible Party |
Type: Sponsor |
||||||
| Has Expanded Access | No | ||||||
| Condition Browse | |||||||
| Arm Group |
Label: Cohort NMDARE-HSE Description: Patients developing clinical autoimmune encephalitis with anti-NMDA antibodies after a herpetic encephalitis, managed by the National Reference Center for Paraneoplastic Syndromes and Autoimmune Encephalitis at the Neurological Hospital of Bron. |
||||||
| Acronym | NMDARE-HSE | ||||||
| Patient Data | No | ||||||
| Study Design Info |
Observational Model: Cohort Time Perspective: Retrospective |
||||||